I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU578405130US, in an envelope addressed to: Box Non-Fee Amendment, Commissioner for Patents, Washington, DC 20231, on the date shown

Docket No.: HO-P01938US0

Group Art Unit: 1644

(PATENT)

TECH CENTER 1600/2900 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Morten Soegaard, et al.

Application No.: 09/463,470

Filed: January 21, 2000 Examiner: Saunders, David

For: CYTOLYSIS OF TARGET CELLS BY

SUPERANTIGEN CONJUGATES INDUCING

T-CELL ACTIVATION

**Assistant Commissioner for Patents** Washington, D.C. 20231

Dear Sir:

The undersigned, Terje Kalland, M.D., Ph.D., hereby declares and states that:

- 1.132 DECLARATION MP S 2100 98

  Talland, M.D., Ph.D., hereby declares and of subject matter. 1. I am a co-inventor of subject matter claimed in the above-referenced patent application.
- I have read the above-referenced application, and I have read the 2. pertinent Office Action.
- My current position is a Chief Scientific Officer at Biovitrum, 3. Lindhagensgatan 133, Stockholm, Sweden.
- The subject matter contained in the reference, Belfrage et al., 4. Immunology (February) 90:183-188, 1997 was material derived and published by myself and the other inventor, Mikael Dohlsten.

Immunology (October) 157:2857-2863, 1996 was material derived and published by myself and the other inventors, Mikael Dohlsten and Peter Lando.

com he de pris if their is admidled friende

25222918.1

- 6. I, Terje Kalland, assert that the inventorship of the above referenced application is correct and I assert that claims 35-46, as made by Terje Kalland, Mikael Dohlsten, Morten Soegaard, Lars Abrahmsen, Goran Forsberg, and Peter Lando, were conceived by the Applicants and in-part published in the Belfrage et al. and Lando et al. reference.
- 7. I declare that all statements made here of my own knowledge are true and all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: October 23, 2007

Terje Kalland, M.D., Ph.D.